Composition and method for inhibiting elastase activity

US2025381131A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2025381131-A1
Application numberUS-202319108546-A
CountryUS
Kind codeA1
Filing dateAug 31, 2023
Priority dateSep 5, 2022
Publication dateDec 18, 2025
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A composition for administration to a subject is disclosed. The composition comprises at least one botanical active component. The botanical active component is present in the composition in an amount effective to inhibit elastase activity in the skin of the subject. The botanical active component comprises at least one extract selected from the group consisting of: i) an extract of Potentilla glabra leaf; ii) an extract of Bombax malabaricum flower; iii) an extract of Amomum villosum seed; iv) an extract of Amomum kravanh fruit; v) an extract of Cornus officinalis fruit; and vi) combinations of i) to v). The composition may be in the form of a topical composition, e.g., for topical application. The composition may also be in the form of an oral composition, e.g., for ingestion. A method of inhibiting elastase activity in the skin of a subject is also provided. The method comprises administering an effective amount of the composition to the subject.

First claim

Opening claim text (preview).

1 . A composition for administration to a subject, the composition comprising at least one botanical active component, wherein the botanical active component comprises at least one extract selected from the group consisting of: i) an extract of Potentilla glabra leaf; ii) an extract of Bombax malabaricum flower; iii) an extract of Amomum villosum seed; iv) an extract of Amomum kravanh fruit; v) an extract of Cornus officinalis fruit; and vi) combinations of i) to v); wherein the botanical active component is present in the composition in an amount effective to inhibit elastase activity in skin of the subject. 2 . The composition according to claim 1 , wherein the botanical active component comprises the extract of Potentilla glabra leaf, optionally wherein the botanical active component consists of the extract of Potentilla glabra leaf. 3 . The composition according to claim 1 , wherein the extract of Potentilla glabra leaf is obtained by alcohol extracting, optionally ethanol extracting, leaves or leaf-based plant material of Potentilla glabra. 4 . The composition according to claim 1 , wherein the composition is substantially to completely free of components obtained from non-leaf-based plant material of Potentilla glabra. 5 . The composition according to claim 1 , wherein the botanical active component comprises the extract of Bombax malabaricum flower, optionally wherein the botanical active component consists of the extract of Bombax malabaricum flower. 6 . The composition according to claim 1 , wherein the extract of Bombax malabaricum flower is obtained by alcohol extracting, optionally ethanol extracting, flowers or flower-based plant material of Bombax malabaricum. 7 . The composition according to claim 1 , wherein the composition is substantially to completely free of components obtained from non-flower-based plant material of Bombax malabaricum. 8 . The composition according to claim 1 , wherein the botanical active component comprises the extract of Amomum villosum seed, optionally wherein the botanical active component consists of the extract of Amomum villosum seed. 9 . The composition according to claim 1 , wherein the extract of Amomum villosum seed is obtained by alcohol extracting, optionally ethanol extracting, seeds or seed-based plant material of Amomum villosum. 10 . The composition according to claim 1 , wherein the composition is substantially to completely free of components obtained from non-seed-based plant material of Amomum villosum. 11 . The composition according to claim 1 , wherein the botanical active component comprises the extract of Amomum kravanh fruit, optionally wherein the botanical active component consists of the extract of Amomum kravanh fruit. 12 . The composition according to claim 1 , wherein the extract of Amomum kravanh fruit is obtained by alcohol extracting, optionally ethanol extracting, fruit or fruit-based plant material of Amomum kravanh. 13 . The composition according to claim 1 , wherein the composition is substantially to completely free of components obtained from non-fruit-based plant material of Amomum kravanh. 14 . The composition according to claim 1 , wherein the botanical active component comprises the extract of Cornus officinalis fruit, optionally wherein the extract of Cornus officinalis is further defined as an extract of Cornus officinalis fruit. 15 . The composition according to claim 1 , wherein the extract of Cornus officinalis fruit is obtained by water extracting (or aqueous extracting) fruit or fruit-based plant material of Cornus officinalis. 16 . The composition according to claim 1 , wherein the extract of Cornus officinalis fruit is obtained by alcohol extracting, optionally ethanol extracting, fruit or fruit-based plant material of Cornus officinalis. 17 . The composition according to claim 1 , wherein the composition is substantially to completely free of components obtained from non-fruit-based plant material of Cornus officinalis. 18 . The composition according to claim 1 , wherein the composition is further defined as a topical composition that is formulated for topical administration to the subject. 19 . The composition according to claim 18 , further comprising a cosmetically acceptable carrier, optionally wherein the cosmetically acceptable carrier is not naturally occurring. 20 . (canceled) 21 . A method of inhibiting elastase activity in skin of a subject, the method comprising administering, optionally topically administering, an effective amount of a composition to the subject, wherein the composition is according to claim 1 . 22 . (canceled)

Assignees

Inventors

Classifications

  • Anti-ageing preparations · CPC title

  • Liliopsida [monocotyledons] · CPC title

  • Malvaceae (Mallow family) · CPC title

  • Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

  • Plant extracts · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2025381131A1 cover?
A composition for administration to a subject is disclosed. The composition comprises at least one botanical active component. The botanical active component is present in the composition in an amount effective to inhibit elastase activity in the skin of the subject. The botanical active component comprises at least one extract selected from the group consisting of: i) an extract of Potentilla…
Who is the assignee on this patent?
Access Business Group Int Llc
What technology area does this patent fall under?
Primary CPC classification A61K8/9789. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Dec 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).